On the recordMarch 9, 2015
Then I would be remiss if I didn't mention at the same time, biosimilar pathways and the fact that we have yet to have that final guidance.
Source
congress.govThen I would be remiss if I didn't mention at the same time, biosimilar pathways and the fact that we have yet to have that final guidance.
Burr emphasizes the need for final guidance on biosimilar pathways.
Share
More from Richard Burr
He was also the author of the Americans With Disabilities Act, helping improve the lives of millions of Americans with disabilities.
I will turn to you when I finish, how about that? I gave you a gracious amount of time. The PEB board determined this was a good solution. And Senator Sanders says he is here looking out for the middle class because nobody does that. Tell…